Dear all,
I am pleased to share with you that the ARISE study results were presented last Friday, 13 August, at the Australasian Diabetes Congress (ADC) 2021 as an oral presentation.
Please see the video below from the presenting author, Prof. Greg Fulcher of the Royal North Shore Hospital in Sydney, Australia, describing the importance of the ARISE study and how these results will benefit people with diabetes globally.
We are very proud of these results and have received excellent feedback from colleagues in headquarters, IO-SO and the regions:
Sabnem Avsar Tuna,
Senior Vice President Region APAC
“When we started in 2019, we had little systematic data on Ryzodeg® outside an RCT setting, despite an extensive phase 3 programme. Therefore, it is a proud moment for us and very useful in our work, that the ARISE study includes four countries from in our region. This is the first multinational real-world study on Ryzodeg®, and I am confident the results will further help clinicians as well as payers to make informed treatment decisions for people with type 2 diabetes.”
Marcin Zychma,
Vice President, Medical and Scientific Affairs, International Operations
“The real world ARISE study fully confirmed the conclusions from Ryzodeg® large clinical programme, most notably presenting substantial improvements in glycaemic control in people with type 2 diabetes initiated on Ryzodeg®, achieved with a low risk of hypoglycaemia. Impressive results of the ARISE study add to the growing evidence for novel treatments of type 2 diabetes.
Being a real world study, ARISE offers evidence as to clinical benefits which treating physicians and patients can expect while intensifying non-insulin treatments to Ryzodeg®, or, when switching to Ryzodeg® from other insulin regimens. Such kind of evidence extends the results obtained in strictly controlled environments of clinical trials and puts them in the context of what is seen in everyday practice of healthcare professionals and in the lives of patients treated with Ryzodeg®.”
Erin Elizabeth Federman
Head of Diabetes Portfolio Strategy, Global Diabetes Commercial Unit
“ARISE has shown us that the efficacy and safety profiles of Ryzodeg® demonstrated in people with T2D in our clinical trials are also seen in a real-world setting. The results from ARISE will be instrumental in ensuring that more patients, both in APAC and around the world, can simplify their lives with a safe, effective, and unique insulin treatment. This data will empower even more physicians to choose Ryzodeg® as the preferred treatment for people living with T2D and seeking powerful and sustained glucose control."
Cem Ozenc
Corporate Vice President, Commercial Affairs & Strategy, Region APAC
“The ARISE study is the very fruit of a strong cross-functional collaboration at both regional and affiliate levels. Today, we are all very proud to see ARISE study being developed from a bright idea to materialize as a very vital RWEs study helping many HCPs and their patients to improve their management of diabetes. Thanks to all of you from very different functions and geographies being well connected and synched around the same goal and making ARISE a reality today.”
Zakia By
Vice President Clinical, Medical & Regulatory, Region APAC
“On successful completion of the study against the backdrop of a raging pandemic, will like to start by thanking the study investigators for being drivers of change for patients with diabetes, even when faced with adversity. Here at Novo Nordisk, we are dedicated to creating value for patients by changing how diabetes is treated and that is exactly what you have all done with ARISE.”
Earlier in July, we completed six results meetings where the primary results were presented to 70 investigators and members of their study teams.
Click on the map to hear a message from the leaders of the six participating affiliates:
We would like to thank all those involved with the study.
Please save the date for the upcoming ARISE symposium which will be held on 11 September 2021, from 15:00 to 16:30 GST.
With best regards,
Shahid (on behalf of the ARISE Study Team)
Dr. Shahid Akhtar, MD, BCMAS, FRSPH
Insulins & Medical Excellence Director
Region Asia Pacific (APAC)